2Department of Pulmonology, University of Health Sciences, Izmir Faculty of Medicine, Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital, İzmir, Türkiye
3Department of Pulmonology, University of Health Sciences, Izmir Faculty of Medicine, Izmir City Hospital, İzmir, Türkiye
Abstract
BACKGROUND AND AIM: Dysregulated glucose metabolism has been implicated in tumor progression and has been associated with unfavorable outcomes in several malignancies. The study explored the prognostic relevance of pretreatment glycemic status in patients with advanced non-small-cell lung cancer (NSCLC).
METHODS: We retrospectively reviewed consecutive patients with NSCLC patients at our center. Baseline fasting plasma glucose (FPG) values obtained before treatment were used to classify patients into normoglycemic, prediabetic, and diabetic groups. For additional analyses, patients were also classified as normoglycemic or hyperglycemic. Overall survival (OS) and progression-free survival (PFS) were assessed using Kaplan–Meier analysis and Cox proportional hazards models.
RESULTS: The cohort comprised 352 patients with NSCLC. In multivariable analysis, FPG being ≥100 mg/dL, involvement of more than one metastatic organ, chemotherapy, and targeted therapy were independently associated with OS (p = 0.007, p < 0.001, p < 0.001, and p < 0.001, respectively). FPG ≥100 mg/dL, involvement of more than one metastatic organ, chemotherapy, and radiotherapy were independently associated with PFS (p = 0.001, p = 0.005, p = 0.015, and p = 0.011, respectively).
CONCLUSION: Pretreatment hyperglycemia was associated with poorer OS and PFS in patients with advanced NSCLC. These findings suggest that baseline glycemic status may provide additional prognostic information; however, prospective studies are needed to clarify this association.
